About this episode

The episode discusses advancements in Parkinson's disease therapy, AI-driven drug discovery, and significant business moves in the biotech sector.

Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion.     Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.       Listed below are links to the GEN stories referenced in this episode of Touching Base :     Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice   GEN , July 9, 2026    Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial   GEN , July 9, 2026&nbsp…

More episodes of Touching Base

• Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Diseases · July 2, 2026 · 36 min
• Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccine · June 18, 2026 · 35 min

Explore listener stats, chart rankings, contacts and more on the Touching Base podcast page.